Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

onabotulinumtoxinA (Botox)

onabotulinumtoxinA is an FDA-licensed reference biologic from AbbVie Inc..

351(a) biologicBLA 103000 AbbVie Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
1991

Reference product

Originator biologic
Ask AI
351(a)BLA 103000

Botox onabotulinumtoxinA

Also under this BLA: Botox Cosmetic

AbbVie Inc.

View full reference-product record
Approved
Marketing
Disc
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for onabotulinumtoxinA from the RCSB Protein Data Bank (PDB 3BTA).

3D molecular structure of onabotulinumtoxinA (PDB entry 3BTA)

Interactive biological assembly from PDB entry 3BTA. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
Ask AI
  1. Reference approval

    Approval date of the reference onabotulinumtoxinA product.

    35 yr 6 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    5 mo ago

onabotulinumtoxinA: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for onabotulinumtoxinA.

Related FDA reference tools

Assyro Intelligence

Ask anything about onabotulinumtoxinA

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo